The optimal treatment of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) and lymph node-negative (N0) breast cancer is currently controversial (4, 5). This evidence concerns the gene NR4A1 and breast cancer.